Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188335 | 0.84 | MEN1 (0.40) | MEN1KMT2ANISCHRENNPC1 | |
| SCHEMBL4820186 | 0.82 | GRM2 (0.39) | NISCHRENGRM2 | |
| SCHEMBL4816886 | 0.80 | HTR1A (0.42) | NISCHGRM2SIRT1SIRT2POLB | |
| SCHEMBL17150852 | 0.73 | NISCH (0.50) | MEN1KMT2ANISCHNPC1RAB9A | |
| SCHEMBL19393131 | 0.73 | NISCH (0.50) | MEN1KMT2ANISCHNPC1RAB9A | |
| SCHEMBL1858436 | 0.72 | HTR1A (0.54) | KMT2AMAPTPOLB | |
| SCHEMBL14224015 | 0.69 | LMNA (0.35) | RENGRM2SIRT1SIRT2MAPT | |
| SCHEMBL27620816 | 0.66 | NISCH (0.43) | MEN1KMT2ANISCHNPC1RAB9A | |
| SCHEMBL23144877 | 0.65 | SIGMAR1 (0.51) | MEN1KMT2A | |
| SCHEMBL1764363 | 0.65 | ALDH1A1 (0.58) | MEN1KMT2ANPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365064-B2 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-29 | — | — | US | disclosed |
| US-7365064-B2 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-29 | — | — | US | disclosed |
| US-7365064-B2 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-29 | — | — | US | disclosed |
| US-20050113368-A1 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2005-05-26 | — | — | US | disclosed |
| EP-1436268-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Reddy's Laboratories Ltd. (IN) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033481-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND PARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113368-A1 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | CYP3A5, HBZ, CYP4Z1 | MEN1 4396/4885KMT2A 2876/4885NISCH 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.